Albala, David <br/><br/>
Clinical Proof-of-concept of a Novel Platform Utilizing Biopsy-derived Live Single Cells, Phenotypic Biomarkers, and Machine Learning Toward a Precision Risk Stratification Test for Prostate Cancer Grade Groups 1 and 2 (Gleason 3 + 3 and 3 + 4).  [electronic resource] 

 -  Urology  02 2019 
 - 198-206 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1527-9995 
<br/><br/><label>Standard No.: </label>10.1016/j.urology.2018.09.032  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Biomarkers, Tumor--genetics<br/>Biopsy<br/>Humans<br/>Machine Learning<br/>Male<br/>Middle Aged<br/>Neoplasm Grading<br/>Phenotype<br/>Proof of Concept Study<br/>Prospective Studies<br/>Prostate--pathology<br/>Prostatic Neoplasms--pathology<br/>Risk Assessment--methods<br/>Tumor Cells, Cultured